Australia: New Powers and Sanctions for the Therapeutic Goods Administration

Last Updated: 8 April 2006
Article by Adam Liberman

The proposed changes under the Therapeutic Goods Amendment Bill 2005

The new Therapeutic Goods Amendment Bill 2005 (Cth) (Bill)1 has far-reaching implications. The Bill will introduce:

  • a new regime of criminal/civil penalty offences
  • higher penalties for such offences, and
  • new enforcement powers

for the Therapeutic Goods Administration (TGA) to deal with manufacturers and sponsors not complying with the Therapeutic Goods Act 1989 (Act), as well as their 'executive officers'.

New criminal/ civil penalty regime

The Bill provides that certain criminal offences2 under the current Act will attract a new criminal/civil penalty regime of sanctions.

Criminal offences

Criminal offences will be re-structured into three main ‘tiers’3 of criminal culpability, depending on the level of fault and consequences of the conduct, as follows:

  1. existing fault-based offences:4 these are the current unchanged fault based criminal offences without any aggravating element
  2. new strict liability offences with an aggravating element: these offences do not carry a fault element but have an aggravating element defined as ‘likely to result in harm or injury to any person’, and
  3. new fault-based offences with a higher aggravating element: these offences have both fault and aggravation elements, the latter being defined as ‘has, will or would result in harm or injury to any person’.

Civil penalties

There will also be new corresponding civil penalty provisions applying to the same act as would result in relevant criminal offences.5 However, the new civil penalties will:

  • have no elements of fault or any aggravating circumstances, and
  • be subject to the civil standard of proof imposed through the Federal Court.6

The same act, if pursued as a civil penalty contravention, will also attract significantly higher penalties than any criminal offences (see below).

Executive officers

Liability for all criminal offences/ civil penalty contraventions under the Bill will also be extended generally to all ‘executive officers’, defined broadly as ‘a person by whatever name called and whether or not a director of the body, who is concerned in or takes part in the management of the body’. Any executive officer who:

  • ‘knew’ about an offence or contravention
  • was in a ‘position to influence the conduct of the corporation in relation to the offence/contravention’, and
  • ‘failed to take all reasonable steps’ to prevent the offence or contravention

may be liable for the maximum penalties applicable to individuals committing the relevant offence or contravention. In determining whether that officer ‘took all reasonable steps’, a court may have regard to that officer’s actions:

  • towards ensuring that ‘employees, agents and contractors have a reasonable knowledge and understanding of the relevant requirements of the Act’, and
  • taken after becoming aware of an offence/ contravention’.7

Higher penalties

Criminal offences under the current Act typically attract a maximum penalty of up to $110,000 and/or 12 months imprisonment. The Bill seeks to:

  • introduce penalties for a tiered criminal offence regime ranging from the same or higher maximum penalties (for the current fault-based offences), to $220,000 (for the new aggravated strict liability offences) and $440,000 and/or five years imprisonment (for the new aggravated fault based offences)
  • impose penalties for corresponding civil penalty contraventions of typically up to $550,000 for individuals and $5.5 million for corporations, and
  • increase penalties for other existing criminal offences of up to $440,000 and/or five years imprisonment.

New enforcement powers

As an alternative to legal proceedings, the TGA will also have the following additional enforcement options to restrain non compliant conduct:

  • infringement notices: these allow the TGA to impose an infringement notice on ‘a person who is alleged to have committed an offence8 or civil penalty contravention’. The maximum penalties entitled to be imposed are:
    1. 1/5th of the maximum penalty for that offence for individuals (and five times that amount for corporations) eg for an offence under the new section 14(1) of the Bill (with a maximum penalty of $440,000), the TGA may issue an infringement notice imposing $88,000 for an individual and $440,000 for a corporation, and
    2. 1/10th of the maximum penalty for the contravention of a civil penalty provision9 eg for a contravention under the new section14A(1) relating to the same conduct (with a maximum penalty of $550,000 for individuals and $5.5 million for corporations), the TGA may issue an infringement notice of $55,000 for individuals and $550,000 for corporations.
  • enforceable undertakings: these allow the TGA to accept a written undertaking from a person ‘in connection with a matter to which the Secretary of the Department of Health and Ageing (Secretary) has a power or function under the Act or regulations’.10 Such undertakings may be enforced by the Federal Court, which can make orders:
    1. to require compliance with the undertaking
    2. to account to the Commonwealth any financial benefit gained from breaching an undertaking
    3. to pay compensation to any person who has suffered loss or damage as a result of the breach, or
    4. that the court otherwise considers appropriate.11

Other elements

The Bill also includes the following other elements:

  • pre-disclosure notices: defendants will be required to provide a written notice of the evidence proposed to be adduced in support of an exception to the offence of importing, manufacturing, or supplying goods not on the Australian Register of Therapeutic Goods prior to the hearing12
  • release of information to public: the secretary will have the power to ‘release to the public therapeutic goods information relating to any decision or action taken under the Act or regulations’,13 and
  • extension to overseas conduct: certain criminal offences will be extended to cover the conduct outside Australia, the result of which occurs in Australia, or is undertaken by an Australian citizen, resident, or corporations incorporated under a law of Australia.14

The US approach

It is interesting to note that the new sanctions and powers of the TGA under the Bill are generally more extensive than those of the comparable US body, the Food and Drug Administration (FDA), a body broadly viewed to be a rigorous regulator.

In particular, under the Federal Food, Drug and Cosmetic Act (U.S.C 21 Chapter 9) (FD&C Act):

a. criminal offences/ civil penalties: whilst the criminal offences enforced by the FDA (‘prohibited acts’) relate to some similar matters,15 there is a much more limited and specific ‘civil penalty’ regime for separate conduct (ie selling drug samples,16 violations of the FD&C Act requirements for devices,17 giving false or misleading statements etc, provision of services by a debarred person18 and failing to comply with certain requirements for electronic product radiation19)

b. penalties for offences/ civil penalty provisions lower: the maximum penalties for criminal offences are generally lower (up to $US1,000 fine and/or one year imprisonment for each violation, with three years and $US10,000 where there is an intent to defraud or mislead and for second offences). (Death, bodily injury or extreme psychological injury may be taken into account in such assessment by judges.20) Similarly, the maximum penalties for civil penalties are significantly lower (ranging from $US1,000 for individuals to up to $US1,000,000 for corporations)21

c. enforcement of civil penalties by court or administratively: unlike what is proposed for the TGA, the limited civil penalties available to the FDA may either be enforced through the courts, or imposed administratively by the Health Secretary (subject to judicial review)22

d. opportunity to be heard: unlike the Bill, there are express requirements for the FDA under the FD&C Act, to notify respondents and to provide an opportunity to answer all allegations and be heard on all disputed issues - both for criminal prosecutions23 and civil penalty contraventions24

e. no executive officer liability: unlike the Bill, there does not appear to be an express extension of liability under the FD&C Act to executive officers although US courts have extended liability to executives when interpreting the FD&C Act25

f. no infringement notice/ enforceable undertaking: unlike the Bill, there are no comparable ‘infringement notice’ or ‘enforceable undertaking’ powers open to the FDA, although:

  • as mentioned, a civil penalty order may be imposed administratively by the Health Secretary, and
  • it is the FDA’s policy to issue ‘warning letters’ before initiating any enforcement action to achieve voluntary compliance although the FDA is not legally obligated to do so,26 and

g. information to public: as compared to the TGA’s proposed new power, the Health Secretary has a more limited power to disseminate information to the public, namely only information regarding drugs and devices which involve imminent danger to health or gross deception of the consumer’.27

Comparable enforcement regimes in the Australian jurisdiction

It is also interesting to note that while there are many aspects of the enforcement and sanctions regime of comparable regulatory bodies in Australia that have some of the powers granted to the TGA under the Bill, no one body appears to hold the full range of powers to the same level of sanctions as the TGA under the Bill.28

Issues arising from the Bill

Amongst the issues arising from the Bill are the following:

  • extension of liability to executives: the broad approach to ‘executive officers’ (whilst not unlike the Environmental Protection Authority’s regulatory regime) means that potentially all those involved in day-to-day management may be personally liable for the breaches committed by their corporation. Where an executive is in a ‘position to influence the conduct of the corporation’, liability may only be avoided if he or she is shown to have taken ‘reasonable steps’ to prevent the offence or contravention, having regard to the actions taken to ensure the corporation’s ‘employees, agents and contractors have a reasonable knowledge and understanding of the requirements to comply with this Act and regulations’ (new section 51C(1)(a)). This means corporations must take care to ensure that all its employees, agents and contractors are properly trained in relation to their specific obligations under the Act. Merely drafting requirements to comply with the Act in contracts with employees, agents and contractors is unlikely to be sufficient to satisfy the new requirements,
  • compliance costs: given that no regulatory impact statement has been made, corporations will have to take into account the currently uncertain compliance costs associated with the Bill. The Bill applies without distinction, to all business (including small businesses), and to all medicines (including the complementary healthcare industry). The compliance costs for all those regulated by the Act will clearly increase, and are likely to at least comprise the following: higher training costs (see above), insurance costs to cover the increased cost of non-compliance, and the cost of greater attention to compliance in general given the substantially increased penalties involved,
  • criminal offences/ civil penalties for same conduct: unlike most other Australian enforcement regimes (except possibly under the Corporations Act), the Bill allows the TGA full discretion to institute either criminal or civil proceedings against a non-complying party for exactly the same conduct. This means that the TGA may choose to institute civil penalty proceedings for the same conduct which holds significantly higher fines, but with a lower burden of proof and without having to show aggravating elements,
  • strict liability offences: given the new range of strict liability offences, corporations will have to take extreme care when providing statements or information to the TGA under the Act eg. when giving product certifications to the TGA in connection with the listing of medicines, or giving statements in relation to registration,
  • double jeopardy issues: while the Bill provides that a person cannot be prosecuted for an offence if he or she has already been imposed with a civil penalty order (and vice versa)29, those who have successfully avoided a criminal conviction may still be faced with civil proceedings being brought against them for a civil penalty contravention (and vice versa),30
  • infringement notices: it is currently uncertain as to how or in what circumstances infringement notices will be imposed by the TGA. The detail has been left to the regulations, which are yet to be drafted. Accordingly, such notices are not currently restricted to minor offences, or even only to strict liability criminal offences, nor to a particular monetary limit.31 Unlike under the Civil Aviation Act 1988 (Cth) or the Corporations Act 2001 (Cth), the TGA is not required to have a ‘reasonable belief’ that an offence or contravention has occurred (instead an ‘allegation’ is sufficient), and unlike under the Corporations Act 2001 (Cth), the TGA is not required to set out particular matters in such notice. Whilst the TGA’s own draft Guidelines (TGA Guidelines)32 address some of these issues, this has not been expressly provided for in the legislation. Further, unlike the FDA’s policy, and the Corporations Act 2001 (Cth), smaller companies are also not assured that their size will be taken into account by the TGA in determining the quantum of penalty to impose under a notice,33
  • enforceable undertakings: those regulated by the Act are also left with uncertainty as to the way undertakings will operate under the Bill. Like infringement notices, there are currently no limitations as to the range of undertakings which the TGA may accept eg the Bill also does not prescribe factors to be taken into account by the TGA in determining to accept or allow a variation of an undertaking.34 However, such a broad approach to undertakings is similar to the approach taken by other Australian enforcement bodies eg. ACCC and ASIC,
  • no merits/judicial review: given that the Bill does not expressly prescribe for merits or judicial review, those faced with a harsh infringement notice, or aggrieved by the secretary’s refusal to withdraw or vary an undertaking at a later stage, will have to face the uncertainty and cost of relying on the Administrative Appeals Tribunal Act 1975 (Cth) and Administrative Decisions (Judicial Review) Act 1977 (Cth) to determine whether the decision can be reviewed. (By contrast, the Act provides expressly for administrative review of certain other decisions of the secretary under section 60). The position under the Bill is however not unlike the situation in other Australian regulatory regimes,
  • information to public: the new power to ‘release information relating to any decision or action taken under the Act or regulations’ is very broad, and unlike for the FDA, is not limited to purposes of protecting health or preventing deception of consumers. The current Act already allows the secretary to release ‘therapeutic goods information necessary to ensure safe use, or relating to reasons of withdrawal’.35 It is therefore unclear how the new powers will be used by the TGA, and
  • pre disclosure notice: this requirement is without precedent in the context of criminal proceedings and it is not clear why a defendant should be placed at such a disadvantage, especially in the criminal law context.


The Bill raises many significant issues. Whilst it is not unusual for new legislation to do so, this Bill marks a paradigm shift in the TGA’s enforcement and sanctions regime. That paradigm shift will not only result in increasing compliance costs and the greater potential for personal liability - a phenomenon which is already part of the Australian business landscape elsewhere - but it also raises the question of whether the right balance has been struck between protecting public health and safety on the one hand, and protecting the legitimate concerns of those that are the principal focus of the Bill.


1. This includes a reference to Therapeutic Goods Amendment Bill No 1 2005 (Cth) and Therapeutic Goods Amendment Bill No 2 2005 (Cth) (which includes minor further amendments by government to unify the TGA’s warrants and search powers into one process to investigate and secure evidence for both criminal and civil proceedings).

The No 1 Bill was introduced to the House of Representatives on 17 August 2005, and passed on 9 November 2005. At the time of writing, the No 1 Bill has been reviewed by Australian Senate Community Affairs Legislative Committee, which put out its report on 7 November 2005, and was formally introduced to the Senate on 28 November 2005 but has not been passed.

2. There are 12 major offences under the current Act relating to matters including breaches of standards, conditions, registration, failures to comply with recovery, withdrawal or recall requirements, providing false or misleading certifications/ statements/ information for registration, manufacture or supply without being included on the Australian Register of Therapeutic Goods or conformity assessment procedures: see table list in the Revised Explanatory Memorandum for the Therapeutic Goods Amendment Bill 2005 at page 6 (EM).

3. Juries will however be entitled to convict for a lesser offence if they acquits the person of the greater offence charged: see Item 141 of Bill, new s53A.

4. These relate to criminal intent or recklessness within the meaning of the Criminal Code Act 1995 (Cth).

5. See items 14 to 129 of the Bill for all changes encompassing the new criminal/civil regime.

6. See item 129 of Bill: new Part 5A-1, s42Y.

7. See item 145 of the Bill, new s54B and 54C.

8. See new s42YJ.

9. See item 129 of Bill: new Part 5A-2.

10. See item 129 of Bill: new Part 5A-3, including the new s42YL.

11. See item 129 of Bill: new Part 5A-3, including the new s42YL.

12. See item 14, new s19C, and item 103, new s41MIA of the Bill. This is designed to provide the prosecution with a more adequate method of assessing the evidence or defence relied upon by the defendant: see EM at Item 14.

13. See Item 157 of the Bill: new s61(5A), as opposed to the current limitation which only allows release of information necessary to ensure the safe use of goods or reasons relating to a withdrawal: see EM at item 157.

14. See item 6, new s5A of the Bill- which applies s15.2 Criminal Code to certain offences under the Bill including offences relating to providing false and misleading statements in an application, manufacturing, supplying, exporting or importing counterfeit goods, and manufacturing. supplying or failing to notify of tampered goods.

15. Eg adulteration and misbranding of drugs or devices, introduction of a new drugs not FDA approved, giving false information, failing to give, refusing access to certain information, or failing to maintain requisite records etc see sec 301 of FD&C Act.

16. See sec 303(b)(2)(A) and (B), of FD&C Act (21 U.S.C. 333) and 303(b)(3) for failing to make a report of convictions under sec 303(b)(2)- with maximum fine of $100,000.

17. See sec 303(f)(1)(A) of FD&C Act (21 U.S.C. 333).

18. See sec 307(a) of FD&C Act (21 U.S.C. 335b).

19. See sec 539(b)(1) of FD&C Act (21 U.S.C. 360pp, see also Part 6-6 of the FDA’s Regulatory Procedures Manual March 2004. Besides the 4 abovementioned civil penalties under FD&C Act, there are only 3 other civil penalties enforced by the FDA under the Public Health Service Act, which relates to such specific matters as biologic recall orders, mammography quality standards, and intentionally destroying, altering or falsifying records for vaccine manufacturers.

20. See page 27, 437 and 4381 of Federal US Sentencing Commission Guidelines Manual effective 1 November 2005.

21. We note that it is FDA policy to consider reduction of penalties for small entities- see Part 5-8 of the FDA’s Regulatory Procedures Manual March 2004, and Guidance document: ‘Reduction of Civil Money Penalties for Small Entities’ which requires the FDA to consider a reduction or waivers of penalties against a small entity.

22. All of the civil penalties can be imposed administratively by the Secretary, with the penalty relating to devices expressly stated as ‘assessed by the Secretary’ after giving notice of the proposal, and providing an opportunity for a hearing and subject to judicial review (see sec 303(3)(A) of FD&C Act (21 U.S.C. 333)). The civil penalty relating to misleading/defrauding the FDA expressly provides for the option of either the Secretary imposing the penalty himself or herself (after an administrative hearing on disputed issues, and subject to judicial review), or to request the Attorney General to institute a civil action in court (see sec 307(a) of FD&C Act (21 U.S.C. 335b)).

23. See sec 305 of FD&C Act (21 U.S.C. 335), Part 7 of Subchapter of Title 21 Food and Drugs Chapter 1 FDA Regulations ‘Enforcement Policy’ which sets out the process by which the FDA must give appropriate notice and opportunity for an accused to show cause why criminal prosecution should not be recommended, and Part 5-2, and 6-5 of the FDA’s Regulatory Procedures Manual March 2004 relating to sec 305 meetings and prosecutions.

24. See endnote 23 above. See also Part 17 Subchapter A of Title 21 Food and Drugs Chapter 1 FDA Regulations entitled ‘Civil Money Penalties Hearings’- which sets out the process by which such administrative hearings are carried out. It provides for an initial decision by a ‘presiding officer’, open to administrative appeal to the Departments Appeal Board, and for judicial review. Administrative hearings generally are also governed by Part 10 and Part 1316, Subchapter of Title 21 Food and Drugs Chapter 1 FDA Regulations both entitled ‘Administrative Practices and Procedures’- which for Part 10 sets out administrative proceedings are initiated, reconsidered and stayed, and the process for court review and citizen petitions, and for Part 1316, sets out some of further processes of such hearings.

25. While this is not express in the FD&C Act, the courts have held that the criminal offences under sec 301 may be prosecuted against both corporations and the ‘persons occupying positions of authority who execute the corporate mission’: see US v Park 421 U.S. 658 (1975)

26. See Chapter 4 of the FDA’s Regulatory Procedures Manual March 2004 which sets out the procedure for issuing warning letters, including that the FDA should consider whether the violations are of regulatory significance, whether prompt correction is likely to occur, etc. So called ‘untitled letters’ may also be issued for violations not meeting the threshold of regulatory significance of a warning letter.

27. See sec 705(a) of FD&C Act (21 U.S.C. 375).

28. We have undertaken a comparison to the regulation of competition law (by the Australian Competition and Consumer Commission), corporation law (by the Australian Securities and Investments Commission), civil aviation law (by the Office of Transport Security and by the Civil Aviation and Safety Authority and environmental law (by the Department of Environment and Heritage).

29. See item 129, new sections 42 YF to YI of Bill.

30. Interesting however, the Corporations Act 2001 (Cth) goes further, allowing criminal proceedings to be commenced even after a person has been sanctioned in civil proceedings- see section 1317M, N, P and Q of Corporations Act 2001 (Cth).

31. This appears to be inconsistent with other Australian enforcement regimes, and is contrary to the recommendations of Part 6 of the ‘Guide to Framing Commonwealth Offences Civil Penalties and Enforcement Powers February 2004’issued by authority of the Minister for Justice and Customs.

32. Submission to the Australian Senate Community Affairs Legislative Committee on the Bill dated October 2005, issued by the Department of Health and Ageing at Part 2, which states that the TGA will only issue infringement notices following a decision to take judicial action, and only in relation to strict liability offences and civil penalty provisions.

33. Section 1317DAE of Corporations Act allows for different penalty amounts to be imposed depending on the entity’s market capitalisation for the relevant day.

34. This is instead set out in Part 3 of the TGA Guidelines, rather than having legislative force.

35. Section 61(7) of Act. Further, the TGA Guidelines states that this power will ‘only being used if there is a public health safety risk’ but this is not set out in the legislation- see Part 4 of TGA Guidelines.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions